This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Epic Sciences Partners With LabCorp To Accelerate European Clinical Sample Processing For Circulating Tumor Cell Technology

Stocks in this article: LH

SAN DIEGO, Jan. 29, 2014 /PRNewswire/ -- Epic Sciences (Epic) announced today an agreement with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) to expedite sample processing for Epic's circulating tumor cell (CTC) technology to support European clinical trials. For Epic's clinical trial partners and customers, LabCorp's Central Laboratory in Mechelen, Belgium is able to quickly process samples, which will then be sent to Epic's GLP certified laboratory in La Jolla, CA for downstream detection and molecular characterization of CTCs. 

"To meet the global demand for Epic's circulating tumor cell technology, this partnership with LabCorp will provide an important access point for all European and Middle Eastern clinical trials sample processing, deposition and banking," said Murali Prahalad, Ph.D., president and CEO of Epic Sciences.  "Working with LabCorp, we have been able to rapidly validate our technology and expand our clinical trial services to Europe for our pharma partners and clinical trial customers."

"We are impressed with the diligence and thoroughness of the Epic team and how Epic's circulating tumor cell technology has swiftly matured to meet LabCorp's quality standards for process and reproducibility," said Dr. Steven M. Anderson, Senior Vice President and Global Head of Clinical Trials of LabCorp. "The ability to detect, quantitate and molecularly characterize circulating tumor cells will provide significant, actionable information in support of oncology clinical trials."

Circulating tumor cells (CTCs) are released from solid tumors and enter the bloodstream. Epic's CTC technology can isolate, count and characterize CTCs from a blood sample to provide an alternate way to identify appropriate patients for clinical trials, select optimal therapeutics given a particular cancer sub-type and understand treatment effectiveness, disease progression and metastatic risk. Epic is currently involved in 27 individual oncology clinical trials occurring around the world and is collaborating with its partners to create companion diagnostic products for oncology drug candidates. Epic's mission is to provide a better way to monitor and personalize cancer treatments.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs